ABEONA THERAPEUTICS INC. Royalty Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Royalty Expense of $1.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. royalty expense for the quarter ending 2025-12-31 was $1.79M.
- ABEONA THERAPEUTICS INC. royalty expense for the quarter ending 2025-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. royalty expense for the quarter ending 2025-06-30 was $100.00K.
- ABEONA THERAPEUTICS INC. royalty expense for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. royalty expense for fiscal 2025 was $1.89M.
- ABEONA THERAPEUTICS INC. royalty expense for fiscal 2023 was $1.60M, a 256.67% increase from fiscal 2022.
- ABEONA THERAPEUTICS INC. royalty expense for fiscal 2022 was $450.00K.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.79M derived: sum of 2 quarters · filed 2026-03-17 | $1.89M derived: sum of 3 quarters · filed 2026-08-13 | $1.89M 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $100.00K derived: sum of 2 quarters · filed 2026-08-13 | $100.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-13 | $100.00K 10-Q · filed 2026-08-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $30.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.60M derived: sum of 3 quarters · filed 2025-03-20 | $1.60M 10-K · filed 2025-03-20 |
| 2023-09-30 | $30.00K 10-Q · filed 2024-11-14 | $1.60M derived: sum of 2 quarters · filed 2024-11-14 | $1.60M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.57M 10-Q · filed 2024-08-12 | $1.57M 10-Q · filed 2024-08-12 | ||
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $100.00K derived: sum of 2 quarters · filed 2024-03-18 | $450.00K derived: sum of 3 quarters · filed 2024-03-18 | $450.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $350.00K derived: sum of 2 quarters · filed 2023-11-13 | $350.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $350.00K 10-Q · filed 2023-08-08 | $350.00K 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |